MiR-22 Suppresses BMP7 in the Development of Cirrhosis

Dong Ji    Bing Li    Qing Shao    Fan Li    Zhongbin Li    Guofeng Chen
Liver Fibrosis Diagnosis and Treatment Center, 302 Hospital of PLA, Beijing, China

Key Words
Cirrhosis • MicroRNAs • miR-22 • Carbon tetrachloride (CCl4) • Bone morphogenic protein 7 (BMP7) • Antisense

Abstract

Background/Aims: New strategies for the prevention and treatment of cirrhosis are urgently needed for improving therapeutic outcome. A role of microRNAs (miRNAs) in the pathogenesis of cirrhosis has been recently acknowledged, whereas the exact involved miRNAs as well as the associated molecular signaling pathways have not been determined. Specifically, the studies on the relationship between miR-22 and bone morphogenic protein 7 (BMP7) in the development of cirrhosis are lacking.

Methods: We examined the correlation of the levels of miR-22 and bone morphogenic protein 7 (BMP7) in the liver biopsies from patients with cirrhosis. We examined overexpression or suppression of miR-22 on BMP7 in hepatocytes. We examined the binding of miR-22 to the 3'-UTR of BMP7 mRNA. Finally, in a carbon tetrachloride (CCl4)-induced cirrhosis model in mice, we gave mice adeno-associated viruses carrying antisense of miR-22, and examined its effects on BMP7 levels and the hallmarks of cirrhosis.

Results: The levels of miR-22 and BMP7 in the liver biopsies from patients were strongly and inversely correlated. MiR-22 inhibited BMP7 expression in hepatocytes, through directly binding the 3'-UTR of BMP7 mRNA. Expression of antisense miR-22 significantly attenuated the levels of liver fibrosis, portal hypertension and sodium retention caused by CCl4, possibly through upregulation of BMP7.

Conclusions: MiR-22 promotes the development of cirrhosis through BMP7 suppression.
with the highest prevalence in North Africa and South Asia [1-4]. HCV-infected people have a very high risk of future development of hepatic fibrosis, or cirrhosis, which often predisposes to hepatocellular carcinoma (HCC) [1-4]. The pathological processes of hepatic fibrosis include injury-induced chronic inflammation, portal hypertension due to impaired blood flow, and disruption of normal hepatic architecture leading to liver dysfunction [1-4].

Animal models have been widely used for studying the molecular mechanisms underlying the pathogenesis of cirrhosis [5-10]. So far, the most commonly used cirrhosis model in mice is carbon tetrachloride (CCl₄) intraperitoneal administration, due to its relatively low toxicity to mice and relatively high reproducibility of cirrhosis development [5-10]. The studies on the molecular mechanism underlying the development of cirrhosis have highlighted a pivotal role of molecules regulating epithelial-mesenchymal transition (EMT) [11], including two multifunctional growth factors from transforming growth factor β (TGFβ) superfamily [12-14], bone morphogenic protein 7 (BMP7) and TGFβ1. While TGFβ1 is a well-established pro-fibrotic factor to induce EMT and fibrosis, BMP7 contradicts the effects of TGFβ1 to reverse EMT and fibrosis [15-19]. Such antagonism has been shown to coordinate the recovery of the injured liver by us [20], and by others [21-25].

Exosomes are small membranous vesicles of diameter ranging from 30 to 100 nm, and can be isolated from various body fluids such as serum, urine, and malignant ascites [26-28]. Exosomes contain unique microRNAs (miRNAs), mRNAs and proteins [26-28]. MiRNAs are small RNA species that range from 19 to 25 nucleotides in length, and are frequently dysregulated in cancer and are associated with cancer development and progression [26-28]. Recent findings have implicated the involvement of miRNAs in the HCV infection and development of cirrhosis [29-37]. These pilot studies have shown upregulation of a number of miRNAs in the fibrotic liver, which may imply a possible involvement of miRNAs in the pathogenesis of cirrhosis. However, the exact underlying regulatory molecular pathways have not been completely elucidated. Moreover, the studies on a member of miRNAs called miR-22 in liver, and specifically its interaction with BMP7, is very limited [38, 39].

Here, we show that the levels of miR-22 and BMP7 in the liver biopsies strongly and inversely correlated. MiR-22 inhibited BMP7 expression in hepatocytes, through direct binding and inhibition on 3’-UTR of BMP7 mRNA. Expression of antisense of miR-22 significantly attenuated the levels of liver fibrosis, portal hypertension and sodium retention caused by CCl₄, possibly through upregulation of BMP7.

### Materials and Methods

#### Specimens from patients

A total of 12 biopsies of cirrhosis from patients were used in this study (Table 1). All specimens had been histologically and clinically diagnosed at Liver Fibrosis Diagnosis and Treatment Center, 302 Hospital of PLA from 2010 to 2014. For the use of these clinical materials for research purposes, prior patient’s consents and approval from the Institutional Research Ethics Committee were obtained.

#### Cell culture

HepG2 is a human hepatocellular carcinoma (HCC) cell line, which was derived from the liver tissue of a 15-year-old Caucasian American male with a well-differentiated hepatocellular carcinoma [40]. These cells are epithelial in morphology, have a modal chromosome number of 55, and are not tumorigenic in nude mice.

#### Table 1. Gender and age of the patients’ sample

<table>
<thead>
<tr>
<th>Gender</th>
<th>Total</th>
<th>Age (M±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>6</td>
<td>43.2±7.8</td>
</tr>
<tr>
<td>Female</td>
<td>6</td>
<td>42.5±6.6</td>
</tr>
</tbody>
</table>
mice [40]. The cells secrete a variety of major plasma proteins, e.g., albumin, transferrin, α2-macroglobulin, α1-antitrypsin, and plasminogen [40]. HepG2 was purchased from American Type Culture Collection (ATCC), and was cultured in Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies, San Jose, CA, USA) supplemented with 20% fetal bovine serum (Invitrogen, Carlsbad, CA, USA).

**Plasmids and adeno-associated virus (AAV) preparation**

Plasmids were successfully constructed using molecular cloning technology. Target sequences (miR-22 sequence: 5'-aguucuucaguggcaagcuuua-3', miR-22 antisense (as-) sequence: 5'-uaaagcuugccacugaagaacu-3', scramble (scr) sequence: 5'-uuguacuacacaaaaguaaug-3') were inserted into pGL3-Basic vector (Promega, Beijing, China). HepG2 cells were transfected with Lipofectamine 2000 reagent (Invitrogen), according to the manufacturer’s instructions.

As-miR-22 and scr were also used to prepare AAV, as has been previously described [41-43]. Briefly, we used a pAAV-CAG-GFP plasmid as a backbone (Clontech, Mountain View, CA, USA), with a packaging plasmid carrying the serotype 8 rep and cap genes and a helper plasmid carrying the adenovirus helper functions (Applied Viromics, LLC, Fremont, CA, USA) to generate AAV in this study. As-miR-22 and scr sequence were cloned using EcoRIII and NheI restriction endonucleases sites in the backbone plasmid. The plasmid also has a GFP reporter. As-miR-22 and scr were connected with GFP with a 2A sequence, which allows for efficient, stoichiometric production of discrete protein products within a single vector through a novel "cleavage" event. Sequencing was performed to confirm the correct orientation of these new plasmids. AAV was prepared by triple transfection of the prepared AAV plasmids, R2C8 (containing AAV2 Rep and AAV8 capsid genes) and plAd5 (containing adenovirus helper genes) into HEK293 cells (ATCC) by Lipofectamine 2000 reagent (Invitrogen). The viruses were purified using CsCl density centrifugation and then titered by a quantitative densitometric dot-blot assay.

**Luciferase-reporter activity assay**

Luciferase-reporters were successfully constructed using molecular cloning technology. Target sequence was inserted into pGL3-Basic vector (Promega) to obtain pGL3-BMP7-3'UTR, which contains the miR-22 binding sequence (BMP7-3'UTR sequence). HepG2-miR-22, or HepG2-scr, or HepG2-as-miR-22 cells were seeded in 24-well plates for 24 hours, after which they were transfected with 1μg of Luciferase-reporter plasmids per well using PEI Transfection Reagent. Then luciferase activities were measured using the dual-luciferase reporter gene assay kit (Promega), according to the manufacturer's instructions.

**Animal manipulations**

All animal procedures were conducted according to the guidelines for the care and use of laboratory animals approved by 302 Hospital of PLA. Female C57BL/6 mice (Charles River Laboratories, China) of 10 weeks of age were given free access to tap water and pelleted mouse diet. Cirrhosis was induced by CCl₄ intraperitoneal administration. Briefly, CCI₄ solution of 50% (v/v) in paraffin oil (Sigma-Aldrich, St. Louis, MO, USA) was administered at a dose of 2ml/kg body weight of the mice, by intraperitoneal injections twice a week for 8 weeks. Each experimental group contained 10 mice. During cirrhosis induction, the mice were provided with 0.3 g/l phenobarbital in drinking water to enhance CCl₄ hepatotoxicity.

**Liver infusion with as-miR-22**

Liver infusion with AAV carrying antisense (as) of miR-22 was performed as has been described before [36, 44-46]. Briefly, the duodenum was exposed to show the common bile duct, after which a microclamp was placed on the common bile duct close to gallbladder. A 31-gauge blunt-ended catheter was then put into the common bile duct through the sphincter of Oddi in the duodenum till the branching of the left and right hepatic duct, which was then clamped with another microclamp to prevent backflow into pancreas and duodenum. The other end of the catheter is connected to a micro-infusion apparatus, which delivers 200µl of AAV containing 10⁻¹⁰ AAV-as-miR22 viral particles, or control AAV-scrambled viral particles, via the catheter at a rate of 5µl/min. After infusion, the hole created by the catheter in the duodenum was closed with 6-0 gauge suture.

**Evaluation of liver fibrosis**

Liver samples were fixed in 10% phosphate-buffered formalin, embedded in paraffin, and stained with the Sirius red staining technique, which stains collagen. Fibrotic areas were counted on 200 random selected
fields corresponding to approximately 6 mm², using an unbiased counting frame, as has been described previously [14]. The percentage of fibrotic area was expressed as number of fibrotic fields divided by total fields, and then multiplied by 100.

**Sodium balance**

The urine sodium concentration (UNa) was assayed by flame photometry (Roika 2000, Roika, UK), and renal sodium excretion (UNaV) was calculated with the following formula: UNaV = UV × UNa, where UV is urine volume. The intake of sodium was assessed by measuring the amounts of food and water consumed. Sodium balance was calculated as (Na+ provided by food and water)-UNaV.

**Portal pressure**

After evaluation of sodium metabolism, under anesthesia, a PE-50 polyvinyl catheter was placed in the cecal vein. The other end of the catheter was connected to a highly sensitive transducer (ADInstruments Shanghai Trading Co. Shanghai, China) to assess portal pressure.

**Quantitative real-time PCR (RT-qPCR)**

miRNAs and total RNAs were extracted from liver specimen or cultured cells with miRNeasy mini kit or RNeasy kit (Qiagen, Hilden, Germany), respectively for cDNA synthesis. No fluid miRNAs were analyzed. Quantitative real-time PCR (RT-qPCR) was performed in duplicates with QuantiTect SYBR Green PCR Kit (Qiagen). All primers were purchased from Qiagen. Data were collected and analyzed with the Rotorgene software accompanying the PCR machine, using 2-ΔΔCt method for quantification of the relative mRNA expression levels. Values of genes were first normalized against α-tubulin, and then compared to controls to get relative values.

**ELISA**

The concentration of BMP7 in the cells and conditioned media was determined by BMP7 ELISA Kit (R&D System, Los Angeles, CA, USA). ELISA was performed according to the instructions of the manufacturer. Briefly, the collected condition media was added to a well coated with primary antibody against BMP7, and then immunosorbed by biotinylated anti-BMP7 antibody at room temperature for 2 hours. The color development catalyzed by horseradish peroxidase was terminated with 2.5 mol/l sulfuric acid and the absorption was measured at 450 nm. The protein concentration was determined by comparing the relative absorbance of the samples with the standards.

**Western blot**

Protein was extracted from the mouse liver with RIPA lysis buffer (1% NP40, 0.1% Sodium dodecyl sulfate (SDS), 100 μg/ml phenylmethylsulfonyl fluoride, 0.5% sodium deoxycholate, in PBS) on ice. The supernatants were collected after centrifugation at 12000 × g at 4°C for 20 min. Protein concentration was determined using a BCA protein assay kit (Bio-rad, China), and whole lysates were mixed with 4 × SDS loading buffer (125 mmol/l Tris-HCl, 4% SDS, 20% glycerol, 100 mmol/l Dithiothreitol (DTT), and 0.2% bromophenol blue) at a ratio of 1:3. Samples were heated at 100°C for 5 min and were separated on SDS-polyacrylamide gels. The separated proteins were then transferred to a PVDF membrane. The membrane blots were first probed with a primary antibody. After incubation with horseradish peroxidase-conjugated second antibody, autoradiograms were prepared using the enhanced chemiluminescent system to visualize the protein antigen. The signals were recorded using X-ray film. Primary antibodies were rabbit anti-BMP7 and anti-α-tubulin (Cell Signaling, San Jose, CA, USA). Secondary antibody is HRP-conjugated anti-rabbit (Jackson ImmunoResearch Labs, West Grove, PA, USA). α-tubulin was used as protein loading controls. The protein levels were first normalized to α-tubulin, and then normalized to control.

**Statistical analysis**

Statistical analyses were performed with SPSS 19.0 software (SSPS Inc., Chicago, IL, USA). All data were statistically analyzed using one-way ANOVA with a Bonferroni correction, followed by Fisher’s Exact Test for comparison of two groups. All values are depicted as mean ± standard deviation, and are considered significant if p < 0.05. Each group contained 10 individuals. Bivariate correlations were calculated by Spearman’s r.
Results

Levels of miR-22 and BMP7 correlated in the liver biopsies with cirrhosis

BMP7 has a well-established role in suppressing progress of cirrhosis, and recently, a regulatory role of miR-22 on BMP7 has been reported in renal fibrosis [38]. Thus, we were prompted to examine whether miR-22 may play a similar role in cirrhosis. We examined the levels of miR-22 and BMP7 in the liver biopsies from patients with cirrhosis. We detected a strong and inverse correlation between the levels of miR-22 and BMP7 in the liver biopsies (Fig. 1, R=0.80, p<0.001). These data suggest presence of a relationship between miR-22 and BMP in the development of cirrhosis.

MiR-22 suppressed BMP7 expression in hepatocytes

We have recently shown that BMP7 contradicts the effects of TGFβ1 to reverse EMT and liver fibrosis [20], and BMP7 in liver is predominantly produced by hepatocytes. Thus, we aimed to figure out whether miR-22 may regulate BMP7 expression in hepatocytes. We used a hepatocyte cell line, HepG2, and overexpressed miR-22 or as-miR-22 in these cells. First, modulation of miR-22 levels by AAV transduction in HepG2 cells was confirmed by RT-qPCR (Fig. 2A). We found that the expression of BMP7 in miR-22-overexpressing HepG2 cells was significantly decreased, while the expression of BMP7 in miR-22-depleted HepG2 cells was significantly increased, as measured by RT-qPCR (Fig. 2B), and by ELISA on either cellular protein (Fig. 2C) or secreted protein (Fig. 2D). These data suggest that miR-22 may regulate BMP expression in hepatocytes.

MiR-22 targets 3'UTR of BMP7 mRNA to inhibit its expression

Since our data suggest that miR-22 may inhibit BMP7 expression, we performed bioinformatics analysis of BMP7 target sequence. Our data suggest that the miR-22 binding sites in the BMP7 mRNA sequence 3'UTR ranged from 129th base site to 159th base site (Fig. 3A). HepG2-miR-22, HepG2-scr (control) and HepG2-as-miR-22 cells were then transfected with 1μg of BMP7-3’UTR Luciferase-reporter plasmid. We found that the luciferase activities in HepG2-as-miR-22 cells were significantly higher than the control scr, while the luciferase activities in HepG2-miR-22 cells were significantly lower than the control scr (Fig. 3B). These data suggest that miR-22 targets 3'UTR of BMP7 mRNA to inhibit its expression.

As-miR-22 significantly alleviated the features of cirrhosis induced by CCl₄

In order to evaluate the inhibitory effect of miR-22 on BMP7 and cirrhosis in vivo, we injected CCl₄ to induce cirrhosis in mice. Afterwards, the mice received hepatic infusion with AAV that carry as-miR-22, or AAV that carry scr as a control, through common bile duct, and were kept for another 4 weeks before analyses (Fig. 4A).

The rather even infection of whole liver was demonstrated by GFP expression due to the presence of a GFP reporter in both AAV-as-miR-22 and AAV-scr (as a control) (Fig. 4B). The knockdown of miR-22 in liver was confirmed by RT-qPCR on liver samples (Fig. 4C). The
knockdown of miR-22 in liver increased BMP7 mRNA levels by about 2.8 folds (Fig. 4C), but increased BMP7 protein levels by about 6.3 folds (Fig. 4D).

At sacrifice, the features of cirrhosis were analyzed in mice that received either as-miR-22 or control scr viruses. The fibrotic area was evaluated after Sirius red staining, showing that knockdown of miR-22 by as-miR-22 significantly decreased the percentage of
the fibrotic area (Fig. 5A). Portal hypertension and sodium metabolism were also assessed, showing that knockdown of miR-22 by as-miR-22 significantly decreased the portal pressure (Fig. 5B) and significantly improved sodium balance (Fig. 5C), probably through an increased sodium excretion (Fig. 5D). These data suggest that as-miR-22 significantly alleviated the features of cirrhosis induced by CCl\textsubscript{4}. This model is thus summarized in a schematic (Fig. 6).

**Discussion**

Recently, we have shown that that mesenchymal stem cells produce high levels of BMP7, which antagonizes TGFβ1-induced development of cirrhosis in mice [20]. Since BMP7 plays a pivotal role in suppressing the development of cirrhosis, here we studied its regulation by miRNAs.

miRNAs are frequently dysregulated in cancer and are associated with cancer development and progression [26-28]. Recent findings have implicated the involvement of miRNAs in the HCV infection and development of cirrhosis. Although the role of miR-22 has not been studied in cirrhosis pathogenesis, it was recently implied in a study on kidney in which the authors used a unilateral ureteral obstruction (UUO) model of kidney fibrosis to elucidate direct regulation of BMP7 by miR-22 binding to the 3’-UTR on mRNA [38]. Importantly, mice with targeted deletion of miR-22 exhibited attenuated renal fibrosis in the UUO model [38]. Primary renal fibroblasts in miR-22-deficient UUO mice demonstrate significant increases in BMP7 expression and presented increased resistance to UUO-

---

**Fig. 4.** Efficient inhibition of miR-22 in the liver. (A) In order to evaluate the inhibitory effect of miR-22 on BMP7 and cirrhosis in vivo, we used a well-established CCl\textsubscript{4}-induced cirrhosis animal model. Mice were i.p. injected of CCl\textsubscript{4} twice per week for 8 weeks. During this period, 0.3 g/L phenobarbital was provided in drinking water to enhance CCl\textsubscript{4} hepatotoxicity. Afterwards, the mice received hepatic infusion with AAV that carry as-miR-22, or scr as a control, through common bile duct, and were kept for another 4 weeks before analyses. (B) Representative image for GFP expression in the liver after viral delivery. (C) RT-qPCR for miR-22 and BMP7 in the liver. (D) Western blot for BMP7 in the liver. *: p<0.05. n=10. Statistics: one-way ANOVA with a Bonferroni correction. Scale bar is 100µm.
mediated fibrosis [38]. This study inspired us to do an examination on liver fibrosis, since BMP7 is known to play a similar anti-fibrotic role in both kidney and liver.

We found that the levels of miR-22 and BMP7 in the liver biopsies strongly and inversely correlated. This result is pretty important, since it demonstrates the presence of miR-22 in fibrotic liver and a possible role of miR-22 in regulating BMP7. To confirm it, we modified miR-22 levels in hepatocytes in vitro. We found that the modification of miR-22 indeed altered BMP7 level. These data suggest that the regulation of BMP7 by miR-22 in hepatocytes may be similar to those in renal cells [38]. Since miRNAs normally target 3′-UTR of mRNA of a gene to inhibit its expression, we analyzed its regulation by miRNAs in the current study. Indeed, our data demonstrate a strong regulatory effect of miR-22 on BMP7 mRNA, similar to what had been found in renal fibrosis model [38], in which the authors found that BMP7 were significantly elevated in the kidneys of the miR-22-knock-out mouse. Importantly, in this study, mice with targeted deletion of miR-22 exhibited attenuated renal fibrosis in the UUO model. Consistent with these in vivo observations, primary renal fibroblast isolated...
from miR-22-deficient UUO mice demonstrated a significant increase in BMP7 expression and their downstream targets.

Then we used a loss-of-function experiment to examine the regulation of BMP7 by miR-22 in vivo in a cirrhosis model. Compared with genetically modified mouse models for cirrhosis, a CCl₄-induced model has some advantages in that it best resembles human liver fibrotic diseases [5-10]. We administered as-miR-22 through common bile duct, rather than through circulation. This method has a lot of advantages, like no first by-pass effect, induction of localized infection without affecting cells from other organs and tissues, less off-target effects, etc. Expression of antisense of miR-22 significantly attenuated the levels of liver fibrosis, portal hypertension and sodium retention caused by CCl₄, possibly through upregulation of BMP7. Our data that show the effects of as-miR-22 on BMP are more pronounced at protein level than at mRNA level and are consistent with the findings that miR-22 targets 3'-UTR of mRNA of BMP7, in which the regulation is more like at protein translation. The relative modest effects on mRNA of BMP7 may be feedback of this regulation. However, our data do not exclude the possibility that miR-22 could be targeting in addition to BMP7 that may contribute to the cirrhosis effect.

Moreover, several other lines have been checked to exclude a possibility of cell-line dependence. Together, these data suggest that inhibition of miR-22 may be a potentially promising therapeutic approach for treating and preventing cirrhosis.

**Acknowledge**

This work was financially supported by Wang Baoen Foundation for Liver Fibrosis Research, NO 434510Z0A10 and National Natural Science Foundation of China, NO 81371799.

**Disclosure Statement**

The authors have declared that no competing interests exist.

**Reference**


